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Primaquine is an essential drug for malaria control and
elimination by being the only drug active against the
liver-reservoir of Plasmodium vivax infections and also
the only drug against the mature sexual stages of Plas-
modium falciparum which are responsible for onward
transmission to mosquitoes. Nevertheless, uncertainty
associated with this drug’s safety results in under-use
due to difficulties with diagnosing glucose-6-phosphate
dehydrogenase deficiency (G6PDd) in point-of-care set-
tings. This common genetic disorder makes patients
susceptible to potentially severe, and occasionally even
fatal, primaquine-induced haemolysis.
Policy shifts towards malaria elimination in recent years
have led to a surge of clinical trials and reviews of histori-
cal data to promote safe primaquine use. This talk will
examine evidence of the drug’s use and outcomes in geo-
graphic regions with distinct epidemiological characteris-
tics. For each setting, the parasite epidemiology, the
population’s G6PDd characteristics, and the current pri-
maquine policies will be discussed. The quality and com-
pleteness of the parasitological, G6PDd and clinical
evidence-bases that inform primaquine policy is exam-
ined; the importance of context-specific evaluations of
primaquine use is emphasized.
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